Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Combination Products Performance Reports

Combination Products Performance Reports Home
          About FDA
          Reports, Manuals, & Forms
          Reports
          Combination Products Performance Reports
          FY 2015 OCP Performance ReportCombination Products Performance Reports FY 2015 OCP Performance Report
  
  	
    Share
    Post
    Linkedin

    Email
    PrintCommissioner’s ReportI am pleased to submit the Food and Drug Administration’s (FDA or the Agency) Fiscal Year (FY) 2015 Annual Report to Congress for the Office of Combination Products (OCP).  This report includes data from the 12th full year since OCP was established, as mandated by the Medical Device User Fee and Modernization Act of 2002, P.L. 107-250 (MDUFMA), enacted on October 26, 2002.Combination products are therapeutic and diagnostic products that combine drugs, devices, and/or biological products.  Technological advances continue to merge product types and blur the historical lines of separation between FDA’s human medical product centers, which are made up of the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), and the Center for Devices and Radiological Health (CDRH).   Combination products involve components that would normally be regulated under different types of regulatory authorities, and frequently by different FDA Centers, which raise regulatory, policy, and review management challenges.  Differences in regulatory pathways for each component can impact the regulatory processes for all aspects of product development and management, including preclinical testing, clinical investigation, marketing applications, manufacturing and quality control, adverse event reporting, promotion and advertising, user fees, and post-approval modifications.OCP continues to enhance the transparency and predictability of the process for assigning combination products to the appropriate lead Center and for the review process.  In this regard, OCP continues to facilitate interactions between industry and FDA to clearly delineate regulatory pathways, monitor and adjust processes to ensure timely and effective premarket review, and ensure the consistent and appropriate postmarket regulation of combination products.  In addition to combination products, OCP also has classification and assignment responsibilities for non-combination drug, device, and biologic products.Combination products are likely to become more complicated as new technologies emerge and existing technologies mature.  Therefore, OCP will continue to focus on the most important issues relating to the regulation of combination products.  OCP is committed to actively assisting industry and FDA reviewers in understanding the complexities of this regulatory area.FDA looks forward to ensuring success in meeting the unique challenges in the review and regulation of combination products.Robert M. Califf, M.DCommissioner of Food and DrugsPrintable Version of the FY 2015 OCP Performance ReportOffice of Combination Products FY 2015 Performance Report

                                                                                  Content current as of:
      03/28/2018Combination Products Performance Reports
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop